We bring back our prior pharmacology discussion because it’s so incredibly important for the conversations that are on the horizon over the next few weeks. In this continuation of our myeloma series, we begin our discussion about treatment options for multiple myeloma, focusing first on pharmacology. We are so thrilled to have a special guest, Kathryn Maples, PharmD, BCOP who is a clinical pharmacy specialist in Multiple Myeloma at the Winship Cancer Institute of Emory Healthcare in Atlanta, Georgia!
Content:
- What are common drugs we use in "triplet regimens"? "quadruple therapy"?
- What considerations must we take into account when prescribing commonly used medications in myeloma?
- How should we counsel our patients?
- What about supportive care?
- How and when do we make dose adjustments?
- This episode is SO eye-opening about the "behind the scenes" of myeloma care that physicians do not see
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube
All content for The Fellow on Call: The Heme/Onc Podcast is the property of Rouleaux University Medical Center and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
We bring back our prior pharmacology discussion because it’s so incredibly important for the conversations that are on the horizon over the next few weeks. In this continuation of our myeloma series, we begin our discussion about treatment options for multiple myeloma, focusing first on pharmacology. We are so thrilled to have a special guest, Kathryn Maples, PharmD, BCOP who is a clinical pharmacy specialist in Multiple Myeloma at the Winship Cancer Institute of Emory Healthcare in Atlanta, Georgia!
Content:
- What are common drugs we use in "triplet regimens"? "quadruple therapy"?
- What considerations must we take into account when prescribing commonly used medications in myeloma?
- How should we counsel our patients?
- What about supportive care?
- How and when do we make dose adjustments?
- This episode is SO eye-opening about the "behind the scenes" of myeloma care that physicians do not see
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube
We bring back our prior pharmacology discussion because it’s so incredibly important for the conversations that are on the horizon over the next few weeks. In this continuation of our myeloma series, we begin our discussion about treatment options for multiple myeloma, focusing first on pharmacology. We are so thrilled to have a special guest, Kathryn Maples, PharmD, BCOP who is a clinical pharmacy specialist in Multiple Myeloma at the Winship Cancer Institute of Emory Healthcare in Atlanta, Georgia!
Content:
- What are common drugs we use in "triplet regimens"? "quadruple therapy"?
- What considerations must we take into account when prescribing commonly used medications in myeloma?
- How should we counsel our patients?
- What about supportive care?
- How and when do we make dose adjustments?
- This episode is SO eye-opening about the "behind the scenes" of myeloma care that physicians do not see
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube
The way that we think about smoldering multiple myeloma (SMM) has continued to see evolution in the plasma cell dyscrasia space. If this diagnosis portends a higher risk of developing multiple myeloma, how should we manage patients to prevent possible end-organ damage? Is it a one-size-fits-all approach or are there some patients who are higher risk for progression than others? We cover this and so much more in this new episode!
**This episode is brought to you by Primum**
Content:
- What is smoldering multiple myeloma (SMM)?
- What are higher risk features of SMM?
- What are landmark studies in SMM?
- To treat or not to treat?
** This episode is brought to you by Primum: http://primum.co/fellows
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube
This week, we continue our updated myeloma series, this time we’ll delve deeper into the spectrum of plasma cell dyscrasias, including defining MGUS, discussing surveillance of MGUS, defining smoldering myeloma (SM). We are slowly inching our discussion towards the diagnosis of Multiple myeloma (MM)!
If you haven’t done so already, we highly recommend listening to episode 140 before jumping into this one!
Content:
- Defining MGUS
- Discussing risk of progression of MGUS to MM
- How to interpret free light chains in renal failure
- How do we monitor MGUS patients?
- When do we do additional testing in MGUS?
- What is smoldering myeloma?
- What are myeloma defining events?
- How do we risk stratify SM patients?
- How do we monitor SM patients?
** Want to review the show notes for this episode and others? Check out our website:
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube
It’s been 3 years since our last myeloma series updates and the reality is, a lot has changed! Instead of releasing an updates episode, we are redoing our prior myeloma series to make sure that you, our listeners, can follow along the way you always have.
In the first episode in our highly-anticipated multiple myeloma series, we begin our discussion about introduction to testing/workup for plasma cell dyscrasias and having our initial discussion about monoclonal gammopathy of undetermined significance (MGUS).
Contents:
- What is a plasma cell ?
- What is a plasma cell dyscrasia?
- What is an "SPEP"?
-What is "immunofixation"?
-What are "serum free light chains"?
-Checking UPEP
-Does everyone need a bone marrow biopsy and/or additional workup?
-What is MGUS?
** Want to review the show notes for this episode and others? Check out our website:
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube
This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we highly recommend listening to part 3 of our follicular lymphoma series.
You may also recall that we discussed these agents in our DLBCL series. Be sure to review our show notes from those episode for some awesome graphics and chart.
Episode contents:
- What are "CAR T" and "bispecific antibodies"?
- What are the approved agents?
- Selection of one therapy over another
- Side effect profiles
**** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
This week, we shift our focus to talking about relapsed/refractory follicular lymphoma. In this episode, we will specifically discuss treatment options other than cellular therapy, which will be an upcoming episode. If you have not done so, we highly recommend listening to part 1 and part 2 of this follicular lymphoma series so that you can better follow this week’s conversation!
Episode contents:
- What is the role of rituximab maintenance therapy?
- What does surveillance after therapy look like?
- What are options for treatment of patients who have relapsed follicular lymphoma?
**** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
This week, we continue our conversation on follicular lymphoma, this time focusing on front line therapy. We discuss how we approach localized and diffuse disease and the data behind why we do what we do.
Episode contents:
- What is the front-line approach to management for localized follicular lymphoma?
- What about diffuse disease in a patient who is asymptomatic? What is the front-line options there?
- What is the front-line management for patients with diffuse disease who are symptomatic?
**** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
This week, we kick off a new series, this time focusing on follicular lymphoma! This series will build on a lot of fundamentals that we discussed in our prior series. In this first episode, we start with an introduction to how to approach management of this disease.
Episode contents:
- What is the best approach to biopsy?
- What is the differential for CD10+ cells on flow?
- How is follicular lymphoma classified?
- What is the workup for a new suspected FL?
**** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
This week, we round out our discussion we started in our prior episode on APLS, this time focusing on management. Stick around until the end to hear Dan and Vivek battle it out about the optimal time to recommend APLS testing for your patients!
If you have not done so already, we highly recommend you check out episode 134 (diagnosis of APLS) prior to jumping into this one!
Episode contents:
- What is the best choice of anticoagulant?
- Is a higher INR better for warfarin?
- Are DOACs acceptable options?
- What is the optimal time to send APLS testing?
**** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
This week, we continue our series focusing on venous thromboembolism. In this episode, we begin our discussion of antiphospholipid syndrome.
Episode contents:
- What is "antiphospholipid antibody syndrome"?
- How do we make this diagnosis?
- What is the optimal time to test for these antibodies?
**** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
This week, we discuss another set of high yield topic for anyone who cares for patients on anticoagulation - how to safely hold anticoagulation prior to a procedure and how to reverse the effects of the drug in the even of an emergent situation. We discuss our approach to how we discuss this with our patients and our medical colleagues! Dan also shares his dotphrases for your reference!
Episode contents:
- How do we approach peri-operative anticoagulation management? When do we hold? How long do we hold? Do they need bridging? No bridging?
- In the case of a severe bleed, how do we reverse the effects of anticoagulation?
**** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
This week, we talk all about hypercoagulable testing - a very common referral in outpatient hematology. Who do we consider testing on? Who should we encourage not to test? We discuss this and more here.
Episode contents:
- What are situations in which to consider hypercoaguable testing?
- What are situations to avoid doing so?
**** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
This week, we kick off a new, highly-anticipated and highly-requested series, covering venous thromboembolism (VTE). In this first episode, we discuss how we make the initial diagnosis and how we approach initial management. As a clinician, you will undoubtedly come across the need to make this decision. This episode and this series will set you up for success!
Episode contents:
-What is venous thromboembolism?
- How do we diagnose patients with VTE?
- How do we initially management patients with VTE?
- How do we select anticoagulants for VTE?
****This episode is sponsored by our Global Research Partners! Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
This week, we welcome Dr. Amar Kishan to our show to discuss the role of radiation oncology in the management of patients with testicular cancer. As our listeners know by now, the management of patients with testicular cancer spans multiple specialities. We always appreciate hearing from our colleagues about their perspective.
Episode contents:
- What are important studies to send to radiation oncology prior to their appointment?
- How radiation is planned for seminoma patients and a discussion of the treatment course
- Implications on spermatogenesis, organ function, and infertility
- Role of proton therapy?
- Emerging therapies
****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
This week, we talk all about disseminated testicular cancer, highlighting our current treatment modalities and why we do what we do. We also cover refractory disease. This episode builds on our prior discussions in Parts 1 and 2, so be sure to check these out if you haven’t already!
Episode contents:
- A history lesson about how we developed our current risk stratification model
- Our current treatment paradigms and regimens for disseminated seminoma and non-seminoma
- To resect or not to resect?
- How we approach relapsed/refractory disease
****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
This week, we continue on our testicular cancer journey, focusing on Stage 1 and 2 disease. If you haven’t done so, we highly recommend checking out Episode 127 for our overview of this disease!
Episode contents:
- What it the approach to stage 1 seminoma and non-seminoa? Radiation? Chemotherapy? Surgery?
- What about stage 2 disease?
- What are the pivotal trials that shape today's treatment landscape?
****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
It’s time for another new series, this time focusing on Testicular Cancer. In this first episode, we lay the foundation for our future discussions and discuss the basics of Testicular Cancer.
Episode contents:
- What are germ cell tumors?
- What are important tumor markers to monitor for germ cell tumors?
- Seminoma vs. Non-seminoma
- Staging of germ cell tumors
- Overview of management
****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
This week, we round out our AML series with a detailed discussion about the approach to management of relapsed and refractory disease. This has been a VERY long road going through all management of AML. We hope that you have continued to build on our discussions week-to-week. An exciting treatment paradigm that is ever-evolving!
Episode contents:
- How do we define primary induction failure in AML?
- What are options for treatment of refractory disease? What is the mechanism of action of these treatment options?
- What are options for relapsed disease?
- What targeted therapies are available for relapsed AML?
****This episode is sponsored by our global research partners! Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
In today’s episode, we discuss how to approach AML treatment for patients who are unfit for intensive therapy.
Episode contents:
- How do we assess fitness for intensive AML?
- What are options for patients who are unfit for intensive chemotherapy for AML?
- What are important genetic mutations are important to check for?
- What are the key trials that inform our management in this space?
- How do we dose venetoclax?
- How do we sequence the available agents?
****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
In today’s episode, we welcome back Dr. Amar Kelkar for part 2 of our two-part discussion on allogeneic transplant. In this episode, we build on our prior discussion regarding transplant, this time focusing on transplant for the treatment of AML.
Episode contents:
- What are the different conditioning regimens available?
- How do we decide which regimen is optimal for our patients?
- What is the role of MRD testing?
- What is the role of maintenance therapy post-transplant?
- What are treatment options for GVHD?
- A discussion on racial disparities in transplant
****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
We bring back our prior pharmacology discussion because it’s so incredibly important for the conversations that are on the horizon over the next few weeks. In this continuation of our myeloma series, we begin our discussion about treatment options for multiple myeloma, focusing first on pharmacology. We are so thrilled to have a special guest, Kathryn Maples, PharmD, BCOP who is a clinical pharmacy specialist in Multiple Myeloma at the Winship Cancer Institute of Emory Healthcare in Atlanta, Georgia!
Content:
- What are common drugs we use in "triplet regimens"? "quadruple therapy"?
- What considerations must we take into account when prescribing commonly used medications in myeloma?
- How should we counsel our patients?
- What about supportive care?
- How and when do we make dose adjustments?
- This episode is SO eye-opening about the "behind the scenes" of myeloma care that physicians do not see
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube
